Nearly three years ago, the Institute of Medicine proposed that pharmaceutical manufacturers adopt a universal dosing schedule that would make it possible for people to take medications at just four times of day: morning, noon, evening and bedtime.
The importance of universal dosing terminology has been emphasized by several investigators [ 19, 20].
We determined the incremental cost effectiveness ratio for moving from a strategy of no vaccination to a strategy of universal two dose vaccination with RIX4414.
Although universal booster dose may not be necessary up to 20 years after the primary vaccination because HBsAg and anti-HBc seropositivity did not increase [ 7], the methods for the prevention of horizontal transmission, such as avoidance of skin tattooing, use of disposable needles, and condom use in sexual contact still need continuous implementation in the adolescent group [ 25].
We caution that, aside from the lack of scientific justification for such an approach, it is not at all clear that adoption of universal low-dose linear assessment approaches is indeed precautionary.
Here we evaluate a single dose universal vaccine strategy using recombinant adenoviruses (rAd) expressing the conserved influenza virus antigens matrix 2 and nucleoprotein.
From October 2007, a universal 30 mg dose was introduced and 40 mg tablets of stavudine were withdrawn from the clinic.
The introduction of a two-dose universal childhood VZV vaccination programme in the Netherlands is being considered.
Nanodots obtained from fixed electron beam irradiation followed a universal size versus beam dose trend, with precursor concentrations from pure SiCl4 to 0%% SiCl4 in CH2Cl2, and electron beam intensity ranges of two orders of magnitude, showing good controllability of the deposition.
Though the majority of subjects initiated HAART prior to the introduction of the universal 30 mg stavudine dose, models were also adjusted for time period in which HAART was initiated (prior to or post October 2007).
